Sep. 9 at 2:18 PM
$CVM Where is the promise here?
-P3 failed all of its endpoints back in 2021.
-A datamined patient subset had to be found to get the FDA to agree to a trial redo.
-Other than this population, no meaningful clinical progress has been made in over 5 years.
-Multiple rounds of dilution and reverse splits because no other pharma or biotech has any interest in multikine.
-The Saudi farce is now over a year old, and on a second "partner" for a catalyst that takes 30 working days to decide on.
-They're about to run out of cash in the next month or so.
There is no hope here. Most, if not all, of the bulls here are multi-year bagholders desperate for any reason to not realize theur losses.
